PharmaCorp Rx Inc.
PCRX.V
TSX
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 614.97% | 456.33% | 13.56% | -3.00% | -43.92% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 883.72% | 549.41% | 13.56% | -3.00% | -43.92% |
| Operating Income | -500.94% | -423.37% | -13.56% | 3.00% | 43.92% |
| Income Before Tax | -664.99% | -720.24% | -9.36% | 14.31% | 58.15% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -665.25% | -720.14% | -9.36% | 14.31% | 58.15% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -665.20% | -721.34% | -9.36% | 14.31% | 58.15% |
| EBIT | -500.94% | -423.37% | -13.56% | 3.00% | 43.92% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -211.70% | -444.90% | -7.54% | -1.79% | 43.71% |
| Normalized Basic EPS | -210.17% | -438.71% | -8.06% | -1.90% | 43.27% |
| EPS Diluted | -211.70% | -444.90% | -7.54% | -1.79% | 43.71% |
| Normalized Diluted EPS | -210.17% | -438.71% | -8.06% | -1.90% | 43.27% |
| Average Basic Shares Outstanding | 159.24% | 44.73% | 1.14% | 35.06% | 101.89% |
| Average Diluted Shares Outstanding | 159.24% | 44.73% | 1.14% | 35.06% | 101.89% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |